Click here for slides on this topic


Body mass index (BMI)

A calculated value (kg/m2) that describes weight in kilograms (kg) in relation to square of the height in meters (m).


The following content matched the glossary term: Body mass index (BMI)

AHA ADA prevention of CVD in T2D - Metabolic Bariatric Surgery for Weight Management

Top

Summary of recommendations for bariatric surgery for obese patients from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AHA ADA prevention of CVD in T2D - Pharmacologic Therapy for Weight Management

Top

Summary of pharmacologic therapy options for weight loss from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AACE 2015 guidelines Obesity Management

Top

Summary of the obesity treatment algorithm, including pharmacologic therapy and bariatric surgery, from the 2015 AACE diabetes guidelines 

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

Endocrine Society obesity clinical practice guideline

Top

Summary of guidelines for managing obesity with pharmacologic therapy from the Endocrine Society.

Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study

Top

Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study. Circulation. 2014;130:820-828.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

FactsAbout-OverweightandObesityandType2Diabetes

Top

 

Patient education handout that discusses how overweight and obesity and type 2 diabetes are linked, causes and health risks of overweight and obesity, and tips for patients who are concerned about their weight.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Body mass index (BMI) Slides Found: 40
Risk Factors for Conversion to Diabetes in Mexican Americans
Global Prevalence of Obesity Among Adults
Cancer Mortality According to Body Mass Index
Assessing Risk: BMI and Waist Circumference
Effect of Sibutramine, Orlistat, and Metformin on Risk Factors for Type 2 Diabetes
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females
INTERHEART: Waist-to-Hip Ratio Is a Better Predictor for MI Than BMI
Prevalence of Overweight/Obesity Among US Adults (NHANES 2003-2004)
Prevalence of Overweight/Obesity Among US Adults by Sex/Ethnicity (NHANES 2003-2004)
Prevalence of Overweight* Among US Children and Adolescents
Framingham Offspring Study: 8-Year Incidence of Type 2 Diabetes by BMI
Cardiovascular Mortality in Patients With Coronary Artery Disease by BMI
Overweight Trends in Children and Adolescents
High-Monounsaturated Fat Diet Vs High-Carbohydrate Diet: Effects on A1C, Glucose, Body Weight
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
SOS Analysis: Design
SOS Analysis: Mean Baseline Characteristics
SOS Analysis: Interaction Between Risk Factors and Treatment
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Look AHEAD: 1-Year Interim Results
Look AHEAD at 1 Year: Interventions
Look AHEAD at 1 Year: Change in Body Weight
Look AHEAD at 1 Year: Change in Fitness Levels
Look AHEAD at 1 Year: Additional Results
Look AHEAD: Design
Look AHEAD: Primary Outcome, Participant Characteristics
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
Diabetes Surgery Study: Design
Metformin Sulfonylureas Cancer Risk Type 2 Diabetes | NDEI